Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 21:28:36时区推断·⟳ 抓取 21:29:45·⚡ 决策 07-23 21:33:41 +3m56s·96.1 天前
IMUNON在AACR会议展示IMNN-001卵巢癌Phase 2数据
会议海报复述OVATION-2研究：IMNN-001联合化疗中位总生存40.5个月对27.6个月，最终分析为45.1个月对30.4个月。
📄 原文Investing.com↗ 原文
IMUNON presents ovarian cancer therapy data at AACR conference
Oil prices top $100 a barrel after Houthis attack Saudi tankers in Red Sea LAWRENCEVILLE, N.J. - IMUNON Inc. (NASDAQ:IM…
不做 IMUNON（IMNN.US）
会议海报复述3月已披露的Phase 2最终OS数据，非新催化；商业化仍待Phase 3和BLA，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司已披露OVATION-2最终数据，中位OS提升由此前11.1个月升至14.7个月。
- 会议时间为7月21日至24日，本条为会议展示同一数据。市场反应:IMNN.US报价1.60美元，较前收仅涨0.63%，过去数日连续下跌。
关键理由
- 会议海报复述OVATION-2研究：IMNN-001联合化疗中位总生存40.5个月对27.6个月，最终分析为45.1个月对30.4个月。
- 关键14.7个月OS提升的最终Phase 2数据公司已在2026年3月25日发布，本次会议展示不是首次披露。
- 公司仍处于Phase 3验证阶段，未产生商业化收入；从现有临床资产到新增收入需先完成OVATION-3、BLA和批准，短期业绩增量为0。
主要风险
- 临床会议重复展示旧数据，短线price-in风险高。
- Phase 2样本112人且最终仍需Phase 3确认，失败或融资摊薄风险未被本次海报消除。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-03-25 · 影响 invalidates
相同最终Phase 2数据已在4个月前披露，削弱本次交易新鲜度。
检索:IMUNON IMNN-001 14.7 month overall survival March 25 2026 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- normalize_ticker · 结果未知
原文全文
展开原文 · 2,030 字
Oil prices top $100 a barrel after Houthis attack Saudi tankers in Red Sea
LAWRENCEVILLE, N.J. - IMUNON Inc. (NASDAQ:IMNN) presented data on its IMNN-001 therapy for advanced ovarian cancer at the inaugural AACR Conference on Drug Discovery and Development held July 21-24, 2026 in Boston, according to a press release statement.
IMNN-001 is a DNA-based interleukin-12 immunotherapy administered weekly over six months. The treatment delivers IL-12 directly to tumor sites rather than systemically.
The company presented findings from its Phase 2 OVATION-2 study, which enrolled 112 patients with newly diagnosed advanced ovarian cancer. The trial compared IMNN-001 combined with neoadjuvant and adjuvant chemotherapy against chemotherapy alone.
The poster reported that patients receiving IMNN-001 plus chemotherapy showed a numerical increase in median overall survival of over 13 months compared to chemotherapy alone, with survival times of 40.5 months versus 27.6 months. The company noted that final results from the trial later showed a 14.7-month increase in median overall survival, with 45.1 months versus 30.4 months.
Translational analyses indicated that IMNN-001 enhanced ratios of CD8+/Tregs and CD8+/CD4+ cells in patients’ tumors and tumor microenvironment. The treatment was described as safe and well-tolerated, with no cytokine release syndrome or higher incidence of immune-related events observed in the experimental arm.
IMUNON is currently conducting a Phase 3 OVATION-3 trial designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer. The company stated that successful results would provide a basis for a Biologics License Application filing.
The company develops DNA-mediated immunotherapies using its TheraPlas® platform technology. IMNN-001 is a DNA plasmid encased in a nanoparticle delivery system that enables local production of IL-12 protein.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LAWRENCEVILLE, N.J. - IMUNON Inc. (NASDAQ:IMNN) presented data on its IMNN-001 therapy for advanced ovarian cancer at the inaugural AACR Conference on Drug Discovery and Development held July 21-24, 2026 in Boston, according to a press release statement.
IMNN-001 is a DNA-based interleukin-12 immunotherapy administered weekly over six months. The treatment delivers IL-12 directly to tumor sites rather than systemically.
The company presented findings from its Phase 2 OVATION-2 study, which enrolled 112 patients with newly diagnosed advanced ovarian cancer. The trial compared IMNN-001 combined with neoadjuvant and adjuvant chemotherapy against chemotherapy alone.
The poster reported that patients receiving IMNN-001 plus chemotherapy showed a numerical increase in median overall survival of over 13 months compared to chemotherapy alone, with survival times of 40.5 months versus 27.6 months. The company noted that final results from the trial later showed a 14.7-month increase in median overall survival, with 45.1 months versus 30.4 months.
Translational analyses indicated that IMNN-001 enhanced ratios of CD8+/Tregs and CD8+/CD4+ cells in patients’ tumors and tumor microenvironment. The treatment was described as safe and well-tolerated, with no cytokine release syndrome or higher incidence of immune-related events observed in the experimental arm.
IMUNON is currently conducting a Phase 3 OVATION-3 trial designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer. The company stated that successful results would provide a basis for a Biologics License Application filing.
The company develops DNA-mediated immunotherapies using its TheraPlas® platform technology. IMNN-001 is a DNA plasmid encased in a nanoparticle delivery system that enables local production of IL-12 protein.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。